Exelixis sues Cipla over generic Cabometyx patents covering 20mg, 40mg strengths

EXELIXIS, INC.

Cipla amended its ANDA to seek approval for 20mg and 40mg generic cabozantinib, adding Paragraph IV certifications.
Exelixis filed a patent infringement complaint on May 9, 2024 in Delaware federal court.
Five patents asserted: U.S. Patent Nos. 8,877,776, 11,091,439, 11,091,440, 11,098,015, 11,298,349.
Exelixis seeks order that FDA approval be no earlier than the latest patent expiration on February 10, 2032.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.